Global Immune Checkpoint Inhibitors Market Poised to Cross US $ 26 Billion by 2029 End

  • 03 Jul 2019

Global immune checkpoint inhibitors market to value over USD 26 Billion by 2029 end and register a CAGR of over 13.6% from 2019 to 2029.

Immune checkpoint inhibitor is an eminent sphere of Immuno-oncology therapies. It is employed in the treatment of cancer by activating and strengthening the body’s immune system to fight the disease. The therapies and inhibitors target the immune system of the body to recognise and retaliate against foreign agents rather than attacking the tumour itself.  

The growth of the global immune checkpoint inhibitors market is attributed to the deteriorating health conditions as well as the rise in exposure to cancerous agents and pollutants in the environment. With the growing geriatric population, cancer as a disease is continually spreading and due to low immunity, it is prevalent in the older generation. 

Medical science- a dynamic field,  cancer cures are discovered regularly and this is projected to drive the growth of the market. With the advancement in technology, the cures are becoming more efficient with minimal pain involved thus further promoting the global market of immune checkpoint inhibitors. 

Along with cancer prevalence, immune checkpoint inhibitors also have received several approvals by the FDA and thus are growing popular as a medical treatment. However, the discovery, treatment and research are expensive and that is expected to retrain the growth of the market in the future. Another aspect limiting the market’s growth is the high incurability rate observed in last stage cancer cases. On the contrary, growing awareness and knowledge helps the public gain an early diagnosis and thus helps the market to foster. 

Various firms in the field of cancer cure treatments have discovered better efficient cures thus helping the market to soar. For instance,  Bristol-Myers Squibb, an American pharmaceutical company, developed a powerful combination of Yervoy, a monoclonal antibody used to treat late-stage, metastatic melanoma, deadly skin cancer and Opdivo, used in the treatment of patients with metastatic non-small cell lung cancer. This combination helped in the cases of patients with metastatic castration-resistant prostate cancer. With several more such discoveries and combinations in the pipeline, the market is poised to soar and gain huge revenue and traction. 

The paradigm shift from conventional mono-therapies to combination Immuno-oncology therapies has benefitted the market.  The global market is competitive yet consolidated due to the strong presence of established players such as Tecentriq who have strategically maintained a consistent position in the market through constant innovation. Keytruda, Imfinzi and Opdivo therapies have received approvals for application for various ailments. To further elucidate, market drivers are constantly undertaking research to form immune checkpoint inhibitors and their combination therapies so as to find more cures. Market influencers are investing in research to further expand the market and explore it’s potential. The advent of innovative immune checkpoint therapies and inhibitors has supported the growth of the market. For instance, Sanofi, in 2015, entered into a new global collaboration, with Regeneron Pharmaceuticals,  to discover, develop and commercialize new antibody. This was done to discover the treatment of phase 2 cutaneous squamous cell carcinoma. Such initiatives are further expected to accelerate the market’s growth. 

Global Immune Checkpoint Inhibitors Market: Segmentation 

By Drug Class,
> PD-1
> PD-L1

The PD-1 inhibitor segment garners the maximum revenue and is anticipated to remain dominant during the forecast period due to the increase in adoption. However, the demand for PD-L1 inhibitor is also projected to exhibit to grow at the highest CAGR. 

By Therapeutic Application 
Lung Cancer
Urothelial Carcinoma
Squamous Cell Carcinoma
Blood Cancer
Other Cancers
The lung cancer segment presently dominates the market and is expected to remain dominant during the forecast period, due to the rise in the prevalence of lung cancer given pollution, rise in smokers and allergies across the globe. 

By Distribution Channel
Hospital Pharmacies
Retail Pharmacies

By Region:
North America 
Latin America
Rest of World

Asia-Pacific presents lucrative trade opportunities for the immune checkpoint inhibitors market, owing to the large population base, the surge in the incidence of cancer, growth in awareness about advanced immune therapy, and improvement of healthcare infrastructure. 

Competitive Landscape: 
Tier 1 players- established companies in the market with a major market share 
Tier 2 players
Emerging players which are growing rapidly
New Entrants  
The major market influencers are AstraZeneca PLC., Bristol-Myers Squibb Company, Eli Lilly and Company (ARMO Biosciences.), Fortress Biotech, Inc. (Checkpoint Therapeutics, Inc.), F. Hoffmann-La Roche Ltd. (Genentech, Inc.), Immutep Limited, Merck & Co., Inc., Merck KGaA (EMD Serono, Inc.), Novartis AG, and Pfizer Inc.
These firms are mainly concentrating on incorporating value addition programs for regulating the customer base through the enhancement of product offerings to suit a diverse range of indications.

FutureWise Takeaways 
Growth prospects 
SWOT analysis
Key trends
Key data points affecting market growth 

Objectives of the Study:
To provide an exhaustive analysis on the global immune checkpoint inhibitors market by drug class, by therapeutic application, by distribution channel, by end-user and by region
To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
To evaluate and forecast micro-markets and the overall market 
To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the Middle East.
To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions
Profiling of companies to evaluate their market shares, strategies, financials and core competencies 


Get unlimited analyst support and customise this study further to your requirements, contact